Senzime AB (publ) executes a directed share issue to two institutions – approximately SEK 28 million added before issue costs
"We are very pleased with the great interest from strong institutions and we are pleased to welcome Handelsbanken Fonder and Länsförsäkringar Fondförvaltning as new shareholders. The directed issue enables us to accelerate our growth and international expansion, and create value for Senzime's shareholders," says Philip Siberg, Chairman of Senzime.
The directed share issue comprises a total of 4,000,000 shares at a subscription price of SEK 6.90 per share. The subscription price has been determined by negotiation between the subscribers and Senzime and corresponds to the closing price as of 12 December 2018. Handelsbanken Fonder (on behalf of Handelsbanken Microcapfond) and Länsförsäkringar Fondförvaltning have subscribed for 2,000,000 shares each, which corresponds to a shareholding of approximately four percent each in Senzime.
Purpose of the issue
The purpose of the issue and the reason for the deviation from shareholders' preferential rights is to bring in more institutional investors in the company and at the same time, in a timely and cost-effective way, enable an acceleration of the international commercialization of Senzime's medical products supported by a strong financial position. The raised funds will be used primarily to further developing the sales organization and to secure working capital needs in connection with production ramp-up.
Shares and share capital
Through the share issue, the total number of shares in the Company will increase by 4,000,000 shares, from 45,077,503 shares, to 49,077,503 shares. The share capital will increase by SEK 500,000, from approximately SEK 5,634,688, to approximately SEK 6,134,688. The share issue represents a dilution effect of approximately eight percent based on the number of shares in the share issue divided by the total number of shares after the share issue.
Danske Bank A/S, Denmark, Sverige Filial has served as financial advisor and the law firm Lindahl as legal advisor in connection with the share issue.
For further information, please contact:
Philip Siberg, Chairman of the Board
Tel +46 707 90 67 34, e-mail: email@example.com
Catrin Molund, Acting CEO
Tel +46 708 11 69 11, e-mail: firstname.lastname@example.org
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on December 12, 2018 at 19:30 CET.